Skip to content

Radioiodine therapy in Graves' disease

Comparison between different fixed and calculated doses of I-131 in treatment of patients with Graves' disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016020217006N1
Enrollment
300
Registered
2017-09-10
Start date
2015-03-01
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves. Thyrotoxicosis with diffuse goiter

Interventions

Intervention 1: Intervention group: Fixed Low Dose (7 mCi)I-131/Single dose. Intervention 2: Intervention group: Fixed High Dose (15 mCi) I-131/Single dose. Intervention 3: Intervention group: Calcula
Treatment - Drugs
Intervention group: Fixed Low Dose (7 mCi)I-131/Single dose
Intervention group: Fixed High Dose (15 mCi) I-131/Single dose
Intervention group: Calculated Dose (100 micro Currie I-131/gr Thyroid tissue) / Single dose
Intervention group: Calculated Dose (150 micro Currie I-131/gr Thyroid tissue) / Single dose
Intervention group: Calculated Dose (200 micro Currie I-131/gr Thyroid tissue) / Single dose
Intervention group: Calculated Dose (300 micro Currie I-131/gr Thyroid tissue) / Single dose

Sponsors

Mashhad University of Medical Sciences, Vice chancellor for research
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age more than 18; Confirmed cases of Graves' disease; No previous history of radioiodine therapy;No previous history of thyroid surgery Exclusion criteria: pregnancy; lactation; severe ophtalmopathy; no desire to join to study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
TSH, T3, T4. Timepoint: 1,3,6,12 months post radioiodine therapy. Method of measurement: Blood test.;Thyroid volume. Timepoint: 1,3,6,12 months post radioiodine therapy. Method of measurement: Ultrasonography.;Thyroid weight. Timepoint: 1,3,6,12 months post radioiodine therapy. Method of measurement: Physical examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Narjess Ayati

Ghaem Nuclear Medicine Reserch Center

AyatiN@mums.ac.ir+98 51 3840 0494

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026